false 0001593184 0001593184 2025-01-15 2025-01-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): January 15, 2025

 

BIOREGENX, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

(State or other jurisdiction of incorporation)

000-56345

(Commission File Number)

30-1912453

(IRS Employer Identification No.)

 

7407 Ziegler Road  
Chattanooga, Tennessee 37421
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (866) 770-4067

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

   

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b). On January 15, 2025, Robert Doran submitted his resignation from his position as director of BioRegenx, Inc., which shall be effective January 31, 2025.

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

BioRegenx, Inc.

(Registrant)

 

Date: January 22, 2025

 

By: /s/ William Resides

Name: William Resides

Title: Chief Executive Officer

 

 

 

 

 2 

 

v3.24.4
Cover
Jan. 15, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 15, 2025
Entity File Number 000-56345
Entity Registrant Name BIOREGENX, INC.
Entity Central Index Key 0001593184
Entity Tax Identification Number 30-1912453
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 7407 Ziegler Road
Entity Address, City or Town Chattanooga
Entity Address, State or Province TN
Entity Address, Postal Zip Code 37421
City Area Code (866)
Local Phone Number 770-4067
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
BioRegenx (PK) (USOTC:BRGX)
Historical Stock Chart
From Feb 2025 to Mar 2025 Click Here for more BioRegenx (PK) Charts.
BioRegenx (PK) (USOTC:BRGX)
Historical Stock Chart
From Mar 2024 to Mar 2025 Click Here for more BioRegenx (PK) Charts.